Medications for sickle cell disease
Pro Research Analysisby 
Searched over 200M research papers
Overview of Medications for Sickle Cell Disease
Sickle cell disease (SCD) is a genetic blood disorder that leads to painful episodes, anemia, and organ damage. Over the past few decades, significant progress has been made in developing medications to manage and modify the course of SCD, with both traditional and newly approved therapies now available 1234+5 MORE.
Hydroxyurea: The Longstanding Standard
Hydroxyurea has been the mainstay of SCD treatment for many years. It works by increasing fetal hemoglobin, which helps prevent the sickling of red blood cells and reduces the frequency of painful vaso-occlusive crises (VOCs) and other complications 1356+2 MORE. Hydroxyurea is effective in both adults and children, and it may also lower the risk of developing sickle cell retinopathy .
Recently Approved Disease-Modifying Medications
L-Glutamine
L-glutamine was approved in 2017 and has been shown to reduce the number of pain crises, hospitalizations, and the need for blood transfusions in SCD patients. It is generally well tolerated and can be used alone or in combination with hydroxyurea 2346+3 MORE.
Crizanlizumab
Crizanlizumab, approved in 2019, is a P-selectin inhibitor that reduces inflammation and the adhesion of sickled cells to blood vessel walls. It decreases the frequency and severity of pain crises and reduces the need for opioid use. Common side effects include infusion reactions, headache, and nausea 2346+3 MORE.
Voxelotor
Voxelotor, also approved in 2019, increases hemoglobin levels and reduces hemolysis by preventing the polymerization of sickle hemoglobin. It has been associated with improved anemia and fewer hemolysis markers. However, voxelotor was recently withdrawn from the market due to concerns that its benefits did not outweigh the risks 2346+3 MORE.
Emerging and Investigational Therapies
Other agents, such as mitapivat and etavopivat (oral pyruvate kinase activators), are under investigation and show potential for improving red blood cell metabolism and reducing complications 46. Additionally, over 30 clinical trials are ongoing to explore new drugs and combination therapies targeting different aspects of SCD pathophysiology .
Curative and Genetic Therapies
While medications can manage symptoms and reduce complications, they are not curative. Hematopoietic stem cell transplantation remains the only established cure, but it is limited by donor availability and potential toxicities 1346+2 MORE. Recently, gene therapies such as exagamglogene autotemcel (exa-cel) and lovotibeglogene autotemcel (lovo-cel) have been approved and show promise for curing SCD, though high costs and limited access remain significant barriers 3569+1 MORE.
Practical Considerations and Challenges
Despite the availability of new medications, challenges such as access, affordability, insurance coverage, and patient adherence limit their widespread use. There is also a lack of clear guidelines on how to select or combine these therapies for individual patients, especially in children and adolescents 16710. The need for more evidence-based practices and real-world data is critical for optimizing treatment .
Conclusion
The landscape of sickle cell disease treatment has expanded significantly, with hydroxyurea, L-glutamine, crizanlizumab, and (until recently) voxelotor offering disease-modifying options. Curative approaches like stem cell transplantation and gene therapy are emerging but remain inaccessible for many. Ongoing research and clinical trials continue to seek better, more accessible, and more effective therapies for all individuals living with SCD 1234+6 MORE.
Sources and full results
Most relevant research papers on this topic